Core Viewpoint - The company achieved a total product revenue of approximately RMB 11.9 billion in 2025, marking a 45% year-on-year increase and surpassing the RMB 10 billion milestone for the first time [1] Group 1: Financial Performance - In the fourth quarter of 2025, the company reported total product revenue of approximately RMB 3.3 billion, reflecting a year-on-year growth of over 60% [1] - The strong growth momentum is expected to continue, driven by the inclusion of six new drugs in the 2026 National Medical Insurance Directory [1] Group 2: Market Impact - The company accounted for a one-time inventory adjustment due to the distribution of products at original prices, following the inclusion of new drugs in the insurance directory [1] - Haitong International expressed that the fourth-quarter performance met their expectations, and they are optimistic about the accelerated market penetration of the six new drugs post-inclusion in the insurance directory [1]

Core Viewpoint - The growth of ArF revenue for the company is dependent on customer demand and the adaptability of its products [1] Group 1 - The company has already generated several hundred thousand in ArF revenue in the first half of 2025, with expectations for continued growth in 2026 [1] - The company offers a wide range of products, which limits its ability to cover all market segments [1] - Some products can be substituted, but complete replacement will take time [1]